208 related articles for article (PubMed ID: 33809700)
1. In-Vitro Application of Magnetic Hybrid Niosomes: Targeted siRNA-Delivery for Enhanced Breast Cancer Therapy.
Maurer V; Altin S; Ag Seleci D; Zarinwall A; Temel B; Vogt PM; Strauß S; Stahl F; Scheper T; Bucan V; Garnweitner G
Pharmaceutics; 2021 Mar; 13(3):. PubMed ID: 33809700
[TBL] [Abstract][Full Text] [Related]
2. Magnetically responsive hybrid nanoparticles for in vitro siRNA delivery to breast cancer cells.
Dalmina M; Pittella F; Sierra JA; Souza GRR; Silva AH; Pasa AA; Creczynski-Pasa TB
Mater Sci Eng C Mater Biol Appl; 2019 Jun; 99():1182-1190. PubMed ID: 30889652
[TBL] [Abstract][Full Text] [Related]
3. Systemic delivery of siRNA by T7 peptide modified core-shell nanoparticles for targeted therapy of breast cancer.
Yu MZ; Pang WH; Yang T; Wang JC; Wei L; Qiu C; Wu YF; Liu WZ; Wei W; Guo XY; Zhang Q
Eur J Pharm Sci; 2016 Sep; 92():39-48. PubMed ID: 27355138
[TBL] [Abstract][Full Text] [Related]
4. Magnetic nanocarriers for the specific delivery of siRNA: Contribution of breast cancer cells active targeting for down-regulation efficiency.
Bruniaux J; Allard-Vannier E; Aubrey N; Lakhrif Z; Ben Djemaa S; Eljack S; Marchais H; Hervé-Aubert K; Chourpa I; David S
Int J Pharm; 2019 Oct; 569():118572. PubMed ID: 31352052
[TBL] [Abstract][Full Text] [Related]
5. Overcoming Akt Induced Therapeutic Resistance in Breast Cancer through siRNA and Thymoquinone Encapsulated Multilamellar Gold Niosomes.
Rajput S; Puvvada N; Kumar BN; Sarkar S; Konar S; Bharti R; Dey G; Mazumdar A; Pathak A; Fisher PB; Mandal M
Mol Pharm; 2015 Dec; 12(12):4214-25. PubMed ID: 26505213
[TBL] [Abstract][Full Text] [Related]
6. Magnetic delivery of antitumor carboplatin by using PEGylated-Niosomes.
Davarpanah F; Khalili Yazdi A; Barani M; Mirzaei M; Torkzadeh-Mahani M
Daru; 2018 Sep; 26(1):57-64. PubMed ID: 30209759
[TBL] [Abstract][Full Text] [Related]
7. Targeting Colorectal Cancer Cells with Niosomes Systems Loaded with Two Anticancer Drugs Models; Comparative In Vitro and Anticancer Studies.
El-Far SW; Abo El-Enin HA; Abdou EM; Nafea OE; Abdelmonem R
Pharmaceuticals (Basel); 2022 Jun; 15(7):. PubMed ID: 35890115
[TBL] [Abstract][Full Text] [Related]
8. Delivery of small interfering RNAs by nanovesicles for cancer therapy.
Pengnam S; Plianwong S; Yingyongnarongkul BE; Patrojanasophon P; Opanasopit P
Drug Metab Pharmacokinet; 2022 Feb; 42():100425. PubMed ID: 34954489
[TBL] [Abstract][Full Text] [Related]
9. Dual-Targeted Therapy in HER2-Overexpressing Breast Cancer with Trastuzumab and Novel Cholesterol-Based Nioplexes Silencing Mcl-1.
Pengnam S; Opanasopit P; Rojanarata T; Yingyongnarongkul BE; Thongbamrer C; Plianwong S
Pharmaceutics; 2023 Oct; 15(10):. PubMed ID: 37896184
[TBL] [Abstract][Full Text] [Related]
10. Synergistic inhibition of breast cancer by co-delivery of VEGF siRNA and paclitaxel via vapreotide-modified core-shell nanoparticles.
Feng Q; Yu MZ; Wang JC; Hou WJ; Gao LY; Ma XF; Pei XW; Niu YJ; Liu XY; Qiu C; Pang WH; Du LL; Zhang Q
Biomaterials; 2014 Jun; 35(18):5028-38. PubMed ID: 24680191
[TBL] [Abstract][Full Text] [Related]
11. Microfluidic manufacturing of different niosomes nanoparticles for curcumin encapsulation: Physical characteristics, encapsulation efficacy, and drug release.
Obeid MA; Khadra I; Albaloushi A; Mullin M; Alyamani H; Ferro VA
Beilstein J Nanotechnol; 2019; 10():1826-1832. PubMed ID: 31579065
[TBL] [Abstract][Full Text] [Related]
12. Combinational siRNA delivery using hyaluronic acid modified amphiphilic polyplexes against cell cycle and phosphatase proteins to inhibit growth and migration of triple-negative breast cancer cells.
Parmar MB; Meenakshi Sundaram DN; K C RB; Maranchuk R; Montazeri Aliabadi H; Hugh JC; Löbenberg R; Uludağ H
Acta Biomater; 2018 Jan; 66():294-309. PubMed ID: 29183848
[TBL] [Abstract][Full Text] [Related]
13. siRNA release kinetics from polymeric nanoparticles correlate with RNAi efficiency and inflammation therapy via oral delivery.
He C; Yue H; Xu L; Liu Y; Song Y; Tang C; Yin C
Acta Biomater; 2020 Feb; 103():213-222. PubMed ID: 31812844
[TBL] [Abstract][Full Text] [Related]
14. Multifunctional Superparamagnetic Nanoparticles: From Synthesis to siRNA Delivery.
Arami S; Mahdavi M; Rashidi MR; Fathi M; Hejazi MS; Samadi N
Curr Pharm Des; 2017; 23(16):2400-2409. PubMed ID: 27799034
[TBL] [Abstract][Full Text] [Related]
15. Flash Nanoprecipitation Fabrication of PEI@Amorphous Calcium Carbonate Hybrid Nanoparticles for siRNA Delivery.
Ren Q; Wang L; Qian W; Chen B; Shuai Q; Yan Y
Macromol Biosci; 2023 Jul; 23(7):e2300085. PubMed ID: 37087721
[TBL] [Abstract][Full Text] [Related]
16. Co-encapsulation of hydrophilic and hydrophobic drugs into niosomal nanocarrier for enhanced breast cancer therapy: In silico and in vitro studies.
Amiri S; Pashizeh F; Moeinabadi-Bidgoli K; Eyvazi Y; Akbari T; Salehi Moghaddam Z; Eskandarisani M; Farahmand F; Hafezi Y; Nouri Jevinani H; Seif M; Mousavi-Niri N; Chiani M; Tavakkoli Yaraki M
Environ Res; 2023 Dec; 239(Pt 2):117292. PubMed ID: 37806480
[TBL] [Abstract][Full Text] [Related]
17. Enhanced endosomal escape of siRNA-incorporating hybrid nanoparticles from calcium phosphate and PEG-block charge-conversional polymer for efficient gene knockdown with negligible cytotoxicity.
Pittella F; Zhang M; Lee Y; Kim HJ; Tockary T; Osada K; Ishii T; Miyata K; Nishiyama N; Kataoka K
Biomaterials; 2011 Apr; 32(11):3106-14. PubMed ID: 21272932
[TBL] [Abstract][Full Text] [Related]
18. Multifunctional peptide-lipid nanocomplexes for efficient targeted delivery of DNA and siRNA into breast cancer cells.
Wan Y; Dai W; Nevagi RJ; Toth I; Moyle PM
Acta Biomater; 2017 Sep; 59():257-268. PubMed ID: 28655658
[TBL] [Abstract][Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
